SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 116 filers reported holding SYNAGEVA BIOPHARMA CORP in Q1 2014. The put-call ratio across all filers is 2.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2014 | $2,981,000 | +176.3% | 32,122 | +104.8% | 0.12% | +192.7% |
| Q3 2014 | $1,079,000 | -68.0% | 15,686 | -51.3% | 0.04% | -62.4% |
| Q2 2014 | $3,374,000 | +66.7% | 32,198 | +32.0% | 0.11% | +70.3% |
| Q1 2014 | $2,024,000 | +27.4% | 24,392 | -2.7% | 0.06% | +4.9% |
| Q3 2013 | $1,589,000 | -74.5% | 25,060 | -83.1% | 0.06% | -77.6% |
| Q2 2013 | $6,233,000 | – | 148,411 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 10,660,432 | $989,182,000 | 10.10% |
| BB BIOTECH AG | 1,130,476 | $104,897,000 | 3.40% |
| BLUE JAY CAPITAL MANAGEMENT, LLC | 80,000 | $7,423,000 | 3.31% |
| Opus Point Partners Management, LLC | 20,002 | $1,856,000 | 1.84% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,847,094 | $356,972,000 | 1.77% |
| SECTORAL ASSET MANAGEMENT INC | 363,884 | $33,765,000 | 1.52% |
| Cormorant Asset Management, LP | 100,000 | $9,279,000 | 1.43% |
| Tekla Capital Management LLC | 223,020 | $20,694,000 | 0.97% |
| Lamond Capital Partners LLC | 15,390 | $1,428,000 | 0.94% |
| Squarepoint Ops LLC | 6,700 | $622,000 | 0.60% |